Geron

Geron sells last drug in pipeline to J&J unit

Geron Corp licensed its cancer compound, the last in its pipeline, to a unit of Johnson & Johnson for up to $935 million, sending its shares up as much as 33 percent in extended trading.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics